[Urokinase and tissue type plasminogen activators and their type-1 inhibitor (PAI-1) in gastric cancer].

Article Details

Citation

Copy to clipboard

Gerstein ES, Shcherbakov AM, Kaz'min AI, Ognerubov NA, Kushlinskii NE

[Urokinase and tissue type plasminogen activators and their type-1 inhibitor (PAI-1) in gastric cancer].

Vopr Onkol. 2003;49(2):165-9.

PubMed ID

12785198 [ View in PubMed

]

Abstract

The levels of urokinase (uPA) and tissue type (tPA) plasminogen activators and their type 1 inhibitor (PAI-1) were determined by immunoassay in tumor cytosols and samples of histologically unaltered adjacent mucosa in gastric cancer patients. Gastric tumor revealed enhanced uPA and PAI-1 matched by decreased tPA in intact mucosa. The expression of uPA and PAI-1 was particularly was high at the later stages of the disease. The concentrations of uPA in tumor tissue increased with age. No significant correlation was established between levels of plasminogen activation system components, on the one hand, and histopathological grading of tumor, on the other.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Urokinase	Plasminogen activator inhibitor 1	Protein	Humans	Yes	Substrate Inducer	Details